ArticleActa neurologica Scandinavica2022
Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.
Article in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Ketamine use in the refractory and super refractory status epilepticus: a systematic review.Frontiers in medicine · 2026Pooled it
- The efficacy and safety of ketamine in the treatment of super-refractory status epilepticus: a systematic review.Journal of neurology · 2024Pooled it
- Ketamine in super-refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features.Epilepsia · 2026Observational
- Review
- Status epilepticus in older adults: A critical review.Epilepsia · 2025Review
- Ketamine in Status Epilepticus: How Soon Is Now?Neurology international · 2025Review
- Safety and Efficacy of Ketamine Without Intubation in the Management of Refractory Seizures: A Case Series.Neurocritical care · 2024Article
- Status epilepticus in the ICU.Intensive care medicine · 2024Review
- Outcomes and Treatment Approaches for Super-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis.JAMA neurology · 2023Article
- The Roles of Glutamate Receptors and Their Antagonists in Status Epilepticus, Refractory Status Epilepticus, and Super-Refractory Status Epilepticus.Biomedicines · 2023Review
- Assessing the Effect of Ketamine on Suprarefractory Status Epilepticus Requires Appropriately Designed Cohort Studies.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.Acta neurologica Scandinavica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStatus epilepticus (SE) persisting despite two anti-seizures medications (ASM) and anesthetics is labeled super refractory (SRSE), correlating with important morbidity and mortality. Its treatment relies on expert opinions. Due to its pharmacological properties, ketamine (KET) has received increasing attention, but data are essentially retrospective.
aimsTo describe an unselected cohort of adults receiving KET for SRSE.
methodsAnalysis of a prospective registry of consecutive SE episodes, identifying SRSE patients receiving ketamine (KET). Comparison with recent adult series including more than 10 patients.
resultsEleven patients received KET after a median of 4 days (range: 2-20); median dose was 5 mg/kg/h (range: 2.5-15). KET provided permanent SE control in three (27%). Previous series, using KET administration delays and doses similar to our cohort, report KET efficacy in 28-96% of cases.
conclusionsWe found a lower SE control rate than existing literature, whose data are, however, often retrospective, potentially selecting patients with less severe SE forms or responding to KET. This might explain outcome differences, as KET administration modalities were comparable with our cohort. Since randomized controlled studies are lacking on this subject, the analysis of this prospective, unselected cohort, if confirmed, suggests a current overestimation of KET efficacy in SRSE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.